EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)
- Maeve A. Hennessy
- , Constantine Gatsonis
- , Heather Jacene
- , Roisin M. Connolly
- , Brian L. Burnette
- , Erica M. Stringer-Reasor
- , Justin Romanoff
- , Alexander Taurone
- , Ciara C. O’Sullivan
- , Huong T. Le-Petross
- , Vered Stearns
- , Amy M. Fowler
- , Shou Ching Tang
- , Karla A. Sepulveda
- , Angela M. DeMichele
- , David A. Mankoff
- , Antonio C. Wolff
- University College Cork
- Brown University
- Dana-Farber Cancer Institute
- St. Vincent Hospital, Green Bay
- University of Alabama at Birmingham
- Mayo Clinic Rochester, MN
- University of Texas MD Anderson Cancer Center
- Johns Hopkins University
- University of Wisconsin-Madison
- Louisiana State University Health Sciences Center
- Baylor College of Medicine
- University of Pennsylvania
Research output: Contribution to journal › Article › peer-review